2m 2m 2m 2m 2m 2m 2m
Pacira BioScienc (PCRX)
NASDAQ
$22.31+$0.05 (+0.25%)
Price as of Jun 03, 2026 5:18 PM EDT- $913.7MMarket Cap
- -15.72%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Pacira BioScienc (PCRX)
$22.31+$0.05 (+0.25%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 722.9M -65.56% | 2.1B +210.99% | 675.0M +1.22% | 666.8M +23.14% | |
Cost of Revenue | 149.7M -12.13% | 170.4M -7.71% | 184.7M -7.34% | 199.3M +42.09% | |
Gross Profit | 573.1M -70.29% | 1.9B +293.36% | 490.3M +4.87% | 467.5M +16.51% | |
Sales and Marketing Expense | 368.8M +25.39% | 294.1M +9.15% | 269.4M +5.86% | 254.5M +27.68% | |
Research and Development Expense | -117.3M +43.81% | -81.6M +6.98% | -76.3M -10.07% | -84.8M +52.66% | |
Depreciation and Amortization Expense | 91.0M +15.53% | 78.8M +4.25% | 75.6M -17.41% | 91.5M +220.52% | |
Total Operating Expenses | 707.2M -8.67% | 774.3M +31.85% | 587.3M -3.21% | 606.8M +34.36% | |
Operating Profit | 19.2M +126.16% | -73.4M -183.69% | 87.7M +46.07% | 60.0M -33.25% | |
Interest Income | 22.7M +15.46% | 19.7M +72.05% | 11.4M +151.96% | 4.5M +406.92% | |
Interest Expense | -17.4M +5.29% | -16.6M -18.40% | -20.3M -49.20% | -40.0M +25.91% | |
Interest Income and Expense and Net | 5.3M +69.42% | 3.1M +135.21% | -8.9M -74.99% | -35.4M +14.84% | |
Total Nonoperating Income and Expense | -2.3M -122.57% | 10.3M +139.52% | -26.0M -44.41% | -46.7M +39.39% | |
Income before Taxes | 16.9M +126.74% | -63.1M -202.28% | 61.7M +363.85% | 13.3M -76.42% | |
Income Taxes | 9.8M -73.01% | 36.5M +84.61% | 19.7M +857.42% | -2.6M -118.07% | |
Extraordinary Items | 11.0M N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 7.0M +107.07% | -99.6M -337.30% | 42.0M +163.72% | 15.9M -62.10% | |
Net Income from Continuing Operations Applicable to Common | 16.9M +126.74% | -63.1M -202.28% | 61.7M +363.85% | 13.3M -76.42% | |
Basic EPS and Net Income | 0.16 +107.44% | -2.15 -336.26% | 0.91 +160.00% | 0.35 -63.16% | |
Diluted EPS and Net Income | 0.16 +107.44% | -2.15 -341.57% | 0.89 +161.76% | 0.34 -63.04% | |
Basic Weighted Average Shares | 44.6M -3.63% | 46.2M +0.05% | 46.2M +1.54% | 45.5M +2.84% | |
Diluted Weighted Average Shares | 45.0M -2.60% | 46.2M -11.03% | 52.0M +11.69% | 46.5M +1.99% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 158.5M -42.72% | 276.8M +80.55% | 153.3M +47.21% | 104.1M -82.22% | |
Short-Term Investments | 79.9M -61.57% | 207.8M +65.90% | 125.3M -32.10% | 184.5M +160.50% | |
Cash and Cash Equivalents and Short-Term Investments | 238.4M -50.80% | 484.6M +73.96% | 278.6M -3.49% | 288.7M -56.03% | |
Total Current Assets | 548.0M -26.46% | 745.1M +46.11% | 510.0M +2.34% | 498.3M -42.46% | |
Accumulated Depreciation | 137.7M +3.59% | 132.9M -1.76% | 135.3M +15.17% | 117.5M +37.82% | |
Property and Plant and Equipment and Net | 140.7M -15.84% | 167.2M -3.89% | 173.9M -5.22% | 183.5M -2.59% | |
Total Long-Term Assets | 140.7M -15.84% | 167.2M -3.89% | 173.9M -5.22% | 183.5M -2.59% | |
Total Assets | 1.3B -18.58% | 1.6B -1.33% | 1.6B -6.35% | 1.7B -18.99% | |
Income Taxes Payable | 4.2M +501.86% | 700,000 N/A | N/A N/A | 0 -100.00% | |
Total Short-Term Debt | 0 -100.00% | 201.8M +2,235.10% | 8.6M -74.32% | 33.6M -91.02% | |
Total Current Liabilities | 120.6M -61.09% | 309.9M +218.25% | 97.4M -34.10% | 147.8M -71.64% | |
Total Long-Term Debt | 372.2M -2.96% | 383.5M -25.35% | 513.8M -21.66% | 655.8M -2.77% | |
Total Long-Term Liabilities | 20.6M +22.33% | 16.8M +23.90% | 13.6M +40.38% | 9.7M -1.81% | |
Total Liabilities | 571.8M -26.23% | 775.2M +10.07% | 704.3M -22.28% | 906.2M -32.62% | |
Retained Earnings | -199.3M -3.41% | -206.4M +93.22% | -106.8M -28.20% | -148.8M -29.80% | |
Total Stockholders Equity | 693.1M -10.95% | 778.3M -10.55% | 870.1M +12.27% | 775.0M +6.11% | |
Total Shares Outstanding | 41.1M -11.08% | 46.2M -0.52% | 46.5M +1.20% | 45.9M +2.67% | |
Cash Flow | |||||
Cash from Operating Activities | 152.0M -19.75% | 189.4M +22.46% | 154.6M +6.45% | 145.3M +15.56% | |
Capital Expenditures | 15.3M +44.16% | 10.6M -29.85% | 15.2M -49.59% | 30.1M -34.43% | |
Cash from Investing Activities | 99.5M +219.46% | -83.3M -207.40% | 77.5M +134.43% | -225.2M +983.14% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -369.6M -2,228.82% | 17.4M +109.49% | -183.0M -54.42% | -401.5M -205.47% | |
Financials Ratio | |||||
Gross Margin | 79.28% -13.71% | 91.88% +26.49% | 72.64% +3.61% | 70.11% -5.38% | |
Operating Margin | 2.65% +175.96% | -3.50% -126.91% | 12.99% +44.30% | 9.00% -45.79% | |
Return on Assets | 0.50% +107.84% | -6.37% -346.99% | 2.58% +204.30% | 0.85% -66.21% | |
Return on Equity | 0.96% +107.92% | -12.08% -336.82% | 5.10% +141.32% | 2.11% -66.01% | |
Revenue Growth | -65.56% -131.07% | 210.99% +17,151.89% | 1.22% -94.71% | 23.14% -11.16% | |
Current Ratio | 4.54 +89.00% | 2.40 -54.09% | 5.24 +55.29% | 3.37 +102.92% | |
Cash Ratio | 1.31 +47.22% | 0.89 -43.27% | 1.57 +123.39% | 0.70 -37.29% | |
Debt-to-Equity Ratio | 0.54 -28.59% | 0.75 +25.25% | 0.60 -32.51% | 0.89 -38.07% | |
Debt-to-Assets Ratio | 0.29 -21.92% | 0.38 +13.56% | 0.33 -19.09% | 0.41 -18.89% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow